Galapagos gains $3.7M for CF drug

The Flemish agency for Innovation by Science and Technology has handed Galapagos $5.1 million (€3.7 million) grant for preclinical drug work on cystic fibrosis. Galapagos will collaborate on this project with the Center for Human Genetics at the KU Leuven. The company says the funding increases the chances that it will have a preclinical drug candidate in 2013. Release

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.